

Signe Leito

Saatja: Villy.NIKOLOVA@edqm.eu
Saatmisaeg: neljapäev, 25. september 2025 16:34
Adressaat: Signe Leito
Teema: Survey: proposed addition of Osimertinib mesilate and Osimertinib mesilate tablets to the WP: EDQM-2025-03783-mail

Järeltegevuse lipp: Järeltegevus
Olekulipp: Lipuga märgitud

Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada.

Please make sure to include in any reply our mail reference: EDQM-2025-03783-mail

For the attention of NPAs
Copy: Presidium
Dear Colleagues,

Please find below the link to a survey being carried out concerning the proposed addition of two monographs to the work programme of Group P4:

Osimertinib mesilate and Osimertinib mesilate tablets

In order to have access to the survey, please copy and paste this link into your Internet browser:

<https://survey.edqm.eu/index.php?r=survey/index&sid=154771&newtest=Y&lang=en>

Deadline for replies: 27 October 2025.

Thank you.

With kind regards
On behalf of Aurélie Barth

Villy Nikolova
Administrative Support Assistant
European Pharmacopoeia Department
EDQM
Council of Europe
Tel.: +33 (0)3 90 21 64 63 / Fax: +33
(0)3 88 41 27 71
<https://www.edqm.eu> / <https://www.edqm.eu/store>
Stay connected with the EDQM

Please make sure to include in any reply our mail reference: EDQM-2025-03783-mail